ArticleThoracic cancer2018
Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.European radiology · 2021Pooled it
- Prognostic comparison of ablation and laser excision in a population-based cohort of stage III-IV pulmonary malignant tumors.Journal of cardiothoracic surgery · 2026Article
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Changes in Respiratory Function over Time after Radiofrequency Ablation for Lung Tumors.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Article
- Treatment Outcomes for Malignant Peripheral Lung Tumours: A Prospective Single-Centre Comparison of Thermal Ablation, Surgery, and Radiotherapy.Medicina (Kaunas, Lithuania) · 2025Article
- Analysis of perioperative risk factors and development of predictive models for complications following CT guided microwave ablation of pulmonary nodules.Scientific reports · 2025Article
- Ablation combined with video-assisted thoracic surgery hybrid technique for multiple primary lung cancer.iScience · 2025Review
- Predicting Survival and Recurrence of Lung Ablation Patients Using Deep Learning-Based Automatic Segmentation and Radiomics Analysis.Cardiovascular and interventional radiology · 2025Article
- A retrospective study of microwave ablation and thoracoscopic surgery for multiple primary lung cancer: a propensity score matching analysis.Frontiers in surgery · 2025Article
- The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.Journal of clinical medicine · 2024Review
- Risk factors for lung parenchyma hemorrhage and hemoptysis during computed tomography-guided microwave ablation in patients with stage I non-small cell lung cancer: A bicentric retrospective study.Thoracic cancer · 2024Article
- The efficacy and safety of percutaneous CT-guided iodine-125 brachytherapy combined with standard chemotherapy and brachytherapy alone for lung malignant nodule: a retrospective comparative cohort study.Journal of thoracic disease · 2024Article
- Safety and local efficacy of computed tomography-guided microwave ablation for treating early-stage non-small cell lung cancer adjacent to bronchovascular bundles.European radiology · 2024Article
- [Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Microwave Ablation of Liver, Kidney and Lung Lesions: One-Month Response and Manufacturer's Charts' Reliability in Clinical Practice.Sensors (Basel, Switzerland) · 2022Article
- CT after Lung Microwave Ablation: Normal Findings and Evolution Patterns of Treated Lesions.Tomography (Ann Arbor, Mich.) · 2022Article
- Cost and effectiveness of microwave ablation versus video-assisted thoracoscopic surgical resection for ground-glass nodule lung adenocarcinoma.Frontiers in oncology · 2022Article
- Microwave ablation therapy assisted by artificial pneumothorax and artificial hydrothorax for lung cancer adjacent to the vital organs.Frontiers in oncology · 2022Article
- Microwave ablation for the management of pulmonary inflammatory myofibroblastic tumor: a case report and literature review.Translational cancer research · 2021Article
- MR imaging of pulmonary lung nodules during one lung flooding: first morphological evaluation using an ex vivo human lung model.Magma (New York, N.Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study was conducted to investigate the effectiveness and cost of computed tomography (CT)-guided percutaneous microwave ablation (MWA) and thoracoscopic lobectomy for stage I non-small cell lung cancer (NSCLC).
methodsWe retrospectively analyzed the data of 46 and 85 patients with stage I NSCLC treated with CT-guided percutaneous MWA or thoracoscopic lobectomy, respectively, at our center from July 2013 to June 2015. Overall survival (OS), disease-free survival (DFS), local control rate, hospital stay, and cost were evaluated. Survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test.
resultsThe one and two-year OS rates were 97.82% and 91.30% and 97.65% and 90.59% in the MWA and lobectomy groups, respectively. The one and two-year DFS rates were 95.65% and 76.09% and 95.29% and 75.29%, respectively. No significant differences were observed in log-rank analysis between the groups (P = 0.169). The hospital stays in the MWA and lobectomy groups were 6.62 ± 2.31 and 9.57 ± 3.19 days, respectively. The costs of MWA and lobectomy were US$3274.50 ± US$233.91 and US$4678.87 ± US$155.96, respectively. The differences were all significant (P = 0.003).
conclusionMWA and thoracoscopic lobectomy for stage I NSCLC demonstrate similar one and two-year OS and DFS, with no significant differences between the two groups. MWA involved a shorter hospital stay and lower cost, thus should be considered a better option for patients with severe cardiopulmonary comorbidity and patients unwilling to undergo surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.